Terms: = Bone cancer AND KEAP1, INrf2, ENSG00000079999, 9817, Q14145, MGC9454, MGC4407, MGC20887, MGC1114, MGC10630, KLHL19, KIAA0132 AND Prognosis
3 results:
1. TRIM22 inhibits osteosarcoma progression through destabilizing NRF2 and thus activation of ROS/AMPK/mTOR/autophagy signaling.
Liu W; Zhao Y; Wang G; Feng S; Ge X; Ye W; Wang Z; Zhu Y; Cai W; Bai J; Zhou X
Redox Biol; 2022 Jul; 53():102344. PubMed ID: 35636015
[TBL] [Abstract] [Full Text] [Related]
2. BMP8A promotes survival and drug resistance via Nrf2/TRIM24 signaling pathway in clear cell renal cell carcinoma.
Yu YP; Cai LC; Wang XY; Cheng SY; Zhang DM; Jian WG; Wang TD; Yang JK; Yang KB; Zhang C
Cancer Sci; 2020 May; 111(5):1555-1566. PubMed ID: 32128917
[TBL] [Abstract] [Full Text] [Related]
3. Expression of the Nrf2 and keap1 proteins and their clinical significance in osteosarcoma.
Zhang J; Wang X; Wu W; Dang H; Wang B
Biochem Biophys Res Commun; 2016 Apr; 473(1):42-46. PubMed ID: 26987716
[TBL] [Abstract] [Full Text] [Related]
